Table 2.
Nanoparticle small interfering RNA delivery targeting pathways involved in therapy resistance
| Nanoparticle type | Active targeting | siRNAa | Compoundsa | Model | References |
|---|---|---|---|---|---|
| Glycol chitosan | – | Bcl-2 | Doxorubicin | Human prostate cancer | [50] |
| LCP | – | c-Myc | Gemcitabine monophosphate | Human lung cancer | [51] |
| LCP | Anisamide to sigma receptors | VEGF | Gemcitabine monophosphate | Human lung cancer | [52] |
| Liposomal | – | MRP1/BCL2 | Doxorubicin | Human ovarian, breast, lung and colon cancer. (in vitro) | [97] |
| Liposomal | Asparagine-glycine-arginine peptide to CD13 | c-Myc | Doxorubicin | Human fibrosarcoma | [98] |
| Liposomal | Anisamide to sigma receptors | VEGF/c-Myc | Doxorubicin | Human ovarian cancer | [99] |
| Liposomal | GC4 scFv antibody | c-Myc/MDM2/VEGF | miR-34a | Murine melanoma | [100] |
| Liposomal | – | Mcl1 | SAHA (Vorinostat) | Human cervical cancer | [101] |
| Liposomal | – | MRP1/BCL2 | Doxorubicin | Human lung cancer | [102] |
| Liposomal | – | BCL2 | d-(KLAKLAK)2 peptide | Murine melanoma | [103] |
| Liposomal | Hyaluronic acid | MRP1 | Doxorubicin | Human breast cancer | [104] |
| DSPE-PEG lipid | Folate | Survivin | Docetaxel | Human liver cancer | [105] |
| Micellar | – | HIF-1α | Doxorubicin (combined treatment; i.e., not in delivery vehicle) | Human prostate cancer | [106] |
| Micellar | – | Plk1 | Paclitaxel | Human breast cancer | [107] |
| Minicell | EGFR antibody | MDR1 | Doxorubicin | Uterine cancer | [108] |
| PDHA | – | Snail/Twist | Paclitaxel | Murine breast cancer | [109] |
| PEI-GO | – | Bcl-2 | Doxorubicin | Human cervical cancer In vitro study only |
[110] |
| PEO-PbAE/PCL | – | P-glycoprotein | Paclitaxel | Human ovarian cancer (in vitro) |
[111] |
| PLGA-PEI | Biotin to biotin receptors | P-glycoprotein | Paclitaxel | Murine breast cancer | [112] |
| PLGA | – | DCAMKL-1 | DAPT (combined treatment; i.e., not in delivery vehicle) | Human colorectal cancer | [113] |
| PLGA | – | REV1/REV3L | Cisplatin prodrug | Human prostate cancer | [114] |
| Mesoporous silica | – | Bcl-2 | Doxorubicin | Human ovarian cancer (in vitro) |
[115] |
| Mesoporous silica | – | P-glycoprotein | Doxorubicin | Human cervical cancer | [116] |
| Mesoporous silica | Hyaluronic acid + PEGA-pVEC peptide | CTGF | Doxorubicin | Human breast cancer | [117] |
BCL2 B cell lymphoma 2, CTGF connective tissue growth factor, DAPT N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, DCAMKL-1 Doublecortin-like and CAM kinase-like 1, DSPE Distearoyl-phosphatidylethanolamine, HIF-1α Hypoxia-inducible factor-1α, LCP lipid/calcium/phosphate, MDR1 multidrug resistance 1, MRP1 multidrug resistance-associated protein 1, PEI-GO polyethylenimine-functionalized graphene oxide, PEG ethylene glycol, PEO-PbAE poly(ethylene oxide)-modified poly(beta-amino ester), PDHA poly[(1,4-butanediol)-diacrylate-β-5-hydroxyamylaminel, PEO-PCL Poly(ethylene oxide)-modified poly(epsilon-caprolactone), PLGA poly(lactic-co-glycolic acid), PLGA-PEI PLGA polyethyleneimine, Plk1 polo-like kinase 1, SAHA suberoylanilide hydroxamic acid, scFv single chain fragment variable, VEGF vascular endothelial growth factor
aCompounds are encapsulated in delivery vehicles unless stated otherwise